Flavocoxid Improves Bleomycin-Induced Respiratory Dysfunction and Pulmonary Fibrosis; In vitro Study

Author : Marwa Salah Zaghloul, Ramy Ahmed Abdel-Salam, Eman Said, Ghada Mohamed Suddek and Hatem Abdel-Rahman Salem

Pulmonary fibrosis; a progressive and fatal lung disorder is a common interstitial lung disease affecting millions of individuals worldwide with a mean survival time of about 3 years. It has been reported to be the most serious side effect observed with bleomycin's (BLM) use as a chemotherapeutic agent. Flavocoxid is a potent anti-inflammatory and anti-oxidant agent. In the current study, flavocoxid has been investigated for its ability to ameliorate BLM-induced pulmonary fibrosis, respiratory and vascular dysfunction in rats. BLM (5 mg/kg) was instilled intra-tracheally and flavocoxid was administered (20 mg/kg) orally for 5 weeks; one week pre- and 4 weeks post BLM instillation. Flavocoxid administration significantly decreased lung contents of Nrf2, HO-1, TLR4, TNF-α, TGF-β1. Moreover, flavocoxid successfully restored vascular response to Kcl, PE and carbacol and tracheal response to carbacol. In conclusion; flavocoxid ameliorated BLM-induced pulmonary fibrosis and improved respiratory functions and can be proposed to be a potential effective therapeutic agent for management of pulmonary fibrosis.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at